Dynavax to Host Webcast Conference Call Tomorrow to Review HEPLISAV-B(TM) Phase 3 Clinical Data

BERKELEY, CA--(Marketwired - January 06, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) will host a conference call and webcast tomorrow morning, January 7, 2016, at 8:30 a.m. EST. Management looks forward to reviewing top-line clinical data from its Phase 3 HEPLISAV-B trial, HBV-23.

To access the conference call by phone, please dial [phone] from the United States and Canada or [phone] internationally. The conference ID is 16055092. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through January 13, 2016, and may be accessed by dialing [phone] from the United States and Canada or [phone] internationally. The replay passcode is 16055092.

To access the live and subsequently archived webcast of the conference call, please go to the Company's website at http://www.dynavax.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.

Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3614
Email contact